Valence 标志
热门
登录

添加到自选股
专业图表

Latigo Biotherapeutics In...

NasdaqGS: LTGO · 实时价格 · USD
19.49
-0.57 (-2.84%)
收盘价： Aug 14, 2026, 3:59 PM
19.49
+0.00%
盘后: 7:34 PM

Latigo Biotherapeutics Inc. (LTGO) Stock Price, Analysis & Data

-2.84%
买价19.1
市值1.17B
营收（TTM）n/a
净利润（TTM）-111.18M
贝塔值n/a
每股收益（TTM）-2.53
市盈率（TTM）n/a
预期市盈率n/a
市净率（TTM）-0.46
市销率（TTM）n/a
Earnings Daten/a
卖价18.69
成交量303,580
20日均量820,550
开盘价20.01
前收盘价20.06
日内区间18.46 - 20.10
52周区间17.22 - 22.47
分析师n/a
目标价n/a
分红n/a
除息日n/a

关于 LTGO

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibito...

[阅读更多]
行业 Biotechnology
板块 Healthcare
上市日期 Aug 7, 2026
员工人数 59
交易所 NasdaqGS
股票代码 LTGO
官网 https://latigobio.com
公司完整简介

财务表现

2025年，Latigo Biotherapeutics的营收为0，较上一年的0增长undefined%。 净利润为-109.17M，增长78.43%。

财务报表
news image

2天前 · 24/7 Wall St.

Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science ...

news image

5天前 · Simply Wall St.

Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued

Latigo Biotherapeutics (LTGO) recently raised US$345.6 million in its IPO, offering 19,200,000 common shares at US$18 each, following publication in the New England Journal of Medicine of clinical dat...